Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:ELDN NASDAQ:MCRB NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.60+1.3%$14.57$11.27▼$20.90$306.08M0.8175,235 shs29,057 shsELDNEledon Pharmaceuticals$3.88+0.1%$3.47$1.35▼$4.60$299.42M0.941.18 million shs383,497 shsMCRBSeres Therapeutics$7.55-0.5%$8.27$6.56▼$29.98$73.04M0.1257,950 shs24,743 shsSRZNSurrozen$24.62-5.9%$28.72$7.60▼$35.00$290.03M0.59106,873 shs85,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.76%-0.96%+3.22%+4.42%+27.64%ELDNEledon Pharmaceuticals-0.77%-0.51%+11.21%+47.71%+22.86%MCRBSeres Therapeutics-0.66%-5.84%+6.91%-13.27%+7.52%SRZNSurrozen-1.13%-3.43%-15.56%-5.90%+231.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.60+1.3%$14.57$11.27▼$20.90$306.08M0.8175,235 shs29,057 shsELDNEledon Pharmaceuticals$3.88+0.1%$3.47$1.35▼$4.60$299.42M0.941.18 million shs383,497 shsMCRBSeres Therapeutics$7.55-0.5%$8.27$6.56▼$29.98$73.04M0.1257,950 shs24,743 shsSRZNSurrozen$24.62-5.9%$28.72$7.60▼$35.00$290.03M0.59106,873 shs85,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.76%-0.96%+3.22%+4.42%+27.64%ELDNEledon Pharmaceuticals-0.77%-0.51%+11.21%+47.71%+22.86%MCRBSeres Therapeutics-0.66%-5.84%+6.91%-13.27%+7.52%SRZNSurrozen-1.13%-3.43%-15.56%-5.90%+231.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.33Sell$12.00-17.78% DownsideELDNEledon Pharmaceuticals 2.40Hold$9.67149.46% UpsideMCRBSeres Therapeutics 2.00Hold$22.00191.58% UpsideSRZNSurrozen 2.80Moderate Buy$42.0070.61% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, SRZN, AMRN, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00 ➝ $44.004/21/2026SRZNSurrozen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SRZNSurrozen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026AMRNAmarin Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/24/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.003/24/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00 ➝ $36.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.43$0.36 per share40.22$21.43 per share0.68ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.58 per shareN/AMCRBSeres Therapeutics$790K92.45$1.07 per share7.02$2.74 per share2.75SRZNSurrozen$3.48M82.13N/AN/A($23.96) per share-1.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)ELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)MCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)SRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%-4,055.04%-154.08%8/14/2026 (Estimated)Latest MCRB, SRZN, AMRN, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 million5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million3/23/2026Q4 2025SRZNSurrozen-$1.2875-$7.59-$6.3025-$23.88$0.66 million$0.53 million3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/12/2026Status updateMCRBSeres Therapeutics-$2.39-$1.89+$0.50-$1.76N/A$0.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46ELDNEledon PharmaceuticalsN/A8.448.44MCRBSeres TherapeuticsN/A1.651.65SRZNSurrozenN/A11.9111.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%ELDNEledon Pharmaceuticals56.77%MCRBSeres Therapeutics59.34%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%ELDNEledon Pharmaceuticals12.30%MCRBSeres Therapeutics4.70%SRZNSurrozen31.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionableMCRBSeres Therapeutics3309.68 million9.23 millionOptionableSRZNSurrozen8011.61 million7.93 millionNot OptionableMCRB, SRZN, AMRN, and ELDN HeadlinesRecent News About These CompaniesHead-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) vs. Surrozen (NASDAQ:SRZN)May 21, 2026 | americanbankingnews.comWe're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn RateMay 17, 2026 | finance.yahoo.comSurrozen (SRZN) price target increased by 10.11% to 43.52May 14, 2026 | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14, 2026 | tipranks.comSurrozen to Present at Upcoming Healthcare Investor ConferenceMay 12, 2026 | globenewswire.comHC Wainwright Estimates Surrozen's Q2 Earnings (NASDAQ:SRZN)May 11, 2026 | marketbeat.comLifesci Capital Has Strong Forecast for Surrozen Q2 EarningsMay 11, 2026 | marketbeat.comWhat is Lifesci Capital's Forecast for Surrozen Q1 Earnings?May 8, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) Releases Earnings Results, Misses Estimates By $10.56 EPSMay 6, 2026 | marketbeat.comSurrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comInsider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of StockMay 6, 2026 | insidertrades.comYang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) StockMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 SharesMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) CEO Craig Parker Sells 4,524 SharesMay 5, 2026 | marketbeat.comSurrozen (SRZN) Projected to Post Quarterly Earnings on FridayMay 1, 2026 | marketbeat.comSurrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short InterestApril 29, 2026 | marketbeat.comSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comTD Cowen initiates coverage of Surrozen (SRZN) with buy recommendationApril 23, 2026 | msn.comSurrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?April 14, 2026 | zacks.comLifeSci Capital Keeps Their Buy Rating on Surrozen (SRZN)March 29, 2026 | theglobeandmail.comSurrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 15,223 SharesMarch 26, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMCRB, SRZN, AMRN, and ELDN Company DescriptionsAmarin NASDAQ:AMRN$14.60 +0.19 (+1.28%) As of 01:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Eledon Pharmaceuticals NASDAQ:ELDN$3.88 +0.01 (+0.13%) As of 01:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Seres Therapeutics NASDAQ:MCRB$7.54 -0.04 (-0.46%) As of 01:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Surrozen NASDAQ:SRZN$24.62 -1.54 (-5.90%) As of 01:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Keeps Winning After Family Dollar Divorce Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Meta's Manus Mess: Why China Blocked the Deal and What It Means Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
